Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
About Lexicon Pharmaceuticals, Inc.
Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. We use proprietary gene knockout technology to systematically discover the physiological functions of genes in mice and to identify which corresponding human genes encode potential targets for therapeutic intervention, or drug targets. For those targets that we consider to have high pharmaceutical value, we engage in programs for the discovery and development of potential small molecule drugs, therapeutic antibodies and therapeutic proteins. Our physiology-based approach to understanding gene function and our use of mouse models in our drug discovery efforts allow us to make highly-informed decisions throughout the drug discovery and development process, which we believe will increase our likelihood of success in discovering breakthrough therapeutics.
We use solution-phase chemistry to generate diverse libraries of optically pure compounds that are targeted against the same pharmaceutically relevant gene families that we address in our Genome5000 program. These libraries are built using highly robust and scalable organic reactions that allow us to generate compound collections of great diversity and to specially tailor the compound collections to address various therapeutic target families. We design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds. We can rapidly reassemble these building blocks to generate optimization libraries when we identify a hit against one of our in vivo-validated targets, enabling us to rapidly optimize those hits and accelerate our medicinal chemistry efforts.
Our medicinal chemistry technology is housed in a state-of-the-art 76,000 square foot facility in Hopewell, New Jersey. Our lead optimization chemistry groups are organized around specific discovery targets and work closely with their pharmaceutical biology counterparts in our facilities in The Woodlands, Texas. The medicinal chemists optimize lead compounds in order to select clinical candidates with the desired absorption, distribution, metabolism, excretion and physicochemical characteristics. We have the capability to profile our compounds using the same battery of in vivo assays that we use to characterize our drug discovery targets. This provides us with valuable detailed information relevant to the selection of the highest quality compounds for clinical development.
Last Updated: 03-16-04
362 articles with Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2019 Financial Results Conference Call and Webcast on March 12, 2020
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2019 financial results on Thursday, March 12, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EST (7:00 a.m. CST) that day to discuss the financial results and to provide a business update.
Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients With Carcinoid Syndrome
Lexicon Pharmaceuticals, Inc., announced real-world data on XERMELO’s® antiproliferative effects in patients with carcinoid syndrome that were presented at the American Society for Clinical Oncology 2020 Symposium.
Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium
Lexicon Pharmaceuticals, Inc., announced that data from a poster highlighting XERMELO® will be presented at the American Society for Clinical Oncology 2020 Symposium.
Lexicon Pharmaceuticals, Inc. today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from the Phase 3 SOTA-EMPA study for sotagliflozin (Zynquista™) in type 2 diabetes.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1), in development for the treatment of neuropathic pain.
Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the completion of a safety review of the initial run-in cohort of the Telotristat Ethyl for Advanced Biliary Tract Cancer, or TELE-ABC, study, which is a Phase 2 clinical study of telotristat ethyl in patients with biliary tract cancer.
In March, the FDA issued a Complete Response Letter for Zynquista as a treatment for type 1 diabetes.
Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA’s Office of New Drugs for Sotagliflozin in Type 1 DiabetesConference Call Today on Monday, December 2, 2019 at 8:00 am EST / 7:00 am CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that the Office of New Drugs of the U.S. Food and Drug Administration (FDA) has reiterated the FDA's prior position and denied Lexicon's appeal of the Complete Response Letter in relation to the New Drug Application for sotagliflozin (ZynquistaTM) in type 1 diabetes.
Lexicon Pharmaceuticals, Inc. announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference
Lexicon Pharmaceuticals, Inc., reported financial results and provided a business update for the three months ended September 30, 2019.
Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2019 financial results on Thursday, November 7, 2019 before market opens.
The deal had the upside potential of $1.7 billion but showed mixed results in three Phase III clinical trials. Sanofi announced it had terminated the collaboration, but Lexicon lashed out, alleging Sanofi’s termination was “invalid” and the company was “in breach of contract.”
The pooled data results came five months after the FDA rejected Zynquista following a split advisory committee vote.
It’s a busy week for the U.S. Food and Drug Administration (FDA) with quite a number of pending drug approvals, several of which were delayed for a variety of reasons. Here’s a look.
RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Lexicon Pharmaceuticals, Inc. between March 11, 2016, and January 17, 2019, inclusive.
LEXICON INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lexicon Pharmaceuticals, Inc.
Yesterday, the Endocrinologic and Metabolic Drugs Advisory Committee had a split vote, 8 to 8, on whether the overall benefits of Zynquista (sotagliflozin) outweiged the risk in order to support approval. This sends things back to the agency to make a final decision, which has a target action dat...
Cell Medica today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Company’s Board of Directors.
Wall Street projects these three biotechs will grow the fastest over the next 12 months.